Insider Selling: Foundation Medicine Inc (FMI) Insider Sells 14,755 Shares of Stock

Foundation Medicine Inc (NASDAQ:FMI) insider Vincent A. Miller sold 14,755 shares of the stock in a transaction dated Wednesday, January 17th. The stock was sold at an average price of $65.31, for a total transaction of $963,649.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Shares of Foundation Medicine Inc (NASDAQ FMI) traded down $0.60 during midday trading on Friday, reaching $66.35. 89,600 shares of the company were exchanged, compared to its average volume of 289,267. The company has a market cap of $2,410.00, a price-to-earnings ratio of -14.84 and a beta of -0.01. Foundation Medicine Inc has a 1-year low of $17.50 and a 1-year high of $74.30. The company has a current ratio of 2.24, a quick ratio of 2.03 and a debt-to-equity ratio of 0.47.

Foundation Medicine (NASDAQ:FMI) last issued its quarterly earnings data on Wednesday, November 1st. The company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.16. The business had revenue of $42.66 million during the quarter, compared to analyst estimates of $37.99 million. Foundation Medicine had a negative net margin of 119.69% and a negative return on equity of 143.18%. The firm’s quarterly revenue was up 45.0% on a year-over-year basis. During the same quarter last year, the business earned ($0.90) EPS. analysts predict that Foundation Medicine Inc will post -4.44 EPS for the current year.

A number of research analysts have recently commented on the stock. BidaskClub raised shares of Foundation Medicine from a “hold” rating to a “buy” rating in a report on Wednesday, December 27th. Zacks Investment Research cut shares of Foundation Medicine from a “buy” rating to a “sell” rating in a report on Wednesday, January 3rd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company’s stock. Foundation Medicine has a consensus rating of “Hold” and an average price target of $45.33.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Legal & General Group Plc increased its position in Foundation Medicine by 8.6% during the 2nd quarter. Legal & General Group Plc now owns 3,442 shares of the company’s stock valued at $138,000 after purchasing an additional 274 shares during the period. The Manufacturers Life Insurance Company increased its position in Foundation Medicine by 3.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,747 shares of the company’s stock valued at $467,000 after purchasing an additional 341 shares during the period. Bank of New York Mellon Corp increased its position in Foundation Medicine by 1.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 61,597 shares of the company’s stock valued at $2,449,000 after purchasing an additional 835 shares during the period. Wells Fargo & Company MN increased its position in Foundation Medicine by 8.8% during the 2nd quarter. Wells Fargo & Company MN now owns 11,510 shares of the company’s stock valued at $458,000 after purchasing an additional 931 shares during the period. Finally, Teachers Advisors LLC increased its position in Foundation Medicine by 5.5% during the 2nd quarter. Teachers Advisors LLC now owns 25,728 shares of the company’s stock valued at $1,023,000 after purchasing an additional 1,341 shares during the period. Institutional investors and hedge funds own 32.68% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by Stock Observer and is owned by of Stock Observer. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.thestockobserver.com/2018/01/19/insider-selling-foundation-medicine-inc-fmi-insider-sells-14755-shares-of-stock.html.

About Foundation Medicine

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.

Insider Buying and Selling by Quarter for Foundation Medicine (NASDAQ:FMI)

Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply